```html

Yttrium‑90 Microsphere‑Induced Pneumonitis

Overview

Yttrium‑90 (Y‑90) microsphere‑induced pneumonitis is an inflammatory reaction of the lung tissue that occurs after Selective Internal Radiation Therapy (SIRT) using Y‑90‑laden microspheres. SIRT, also known as radio‑embolization, is a minimally invasive treatment for primary liver cancer (hepatocellular carcinoma) and liver‑dominant metastases (e.g., colorectal cancer). The microspheres are infused into the hepatic artery, where they lodge in the tumor’s microvasculature and deliver high‑dose beta radiation locally. In a small subset of patients, a fraction of the microspheres escape the liver and embolize the pulmonary circulation, depositing radiation in lung parenchyma and triggering pneumonitis.

Who it affects: Most cases are seen in adults undergoing SIRT for liver malignancies, typically aged 50–75 years. The condition is rare – reported incidence ranges from 0.5 % to 2 % in large series (Manchester et al., 2020; Mayo Clinic).

Prevalence: Among the >30,000 patients treated worldwide with Y‑90 radio‑embolization, fewer than 600 have been documented with clinically significant pneumonitis. The risk is higher when cumulative lung dose exceeds 30 Gy, a threshold set by the National Cancer Institute (NCI).

Symptoms

Symptoms usually develop 2 weeks to 3 months after the procedure, but delayed presentations up to 6 months have been described. The clinical picture can range from mild discomfort to severe respiratory failure.

Common symptoms

• Dyspnea (shortness of breath): Often exertional at first, progressing to rest dyspnea.
• Cough: Usually dry, non‑productive, but may become mildly productive.
• Fever: Low‑grade (38–38.5 °C) without an obvious infectious source.
• Chest tightness or pleuritic pain: Sharp pain that worsens with deep breathing.
• Fatigue/Generalized weakness: Due to reduced oxygenation.

Less common but important symptoms

• Wheezing or audible crackles on auscultation.
• Hypoxia (oxygen saturation < 90 % on room air).
• Weight loss (if pneumonitis persists > 4 weeks).
• Hemoptysis (rare, may indicate concomitant pulmonary hemorrhage).

Causes and Risk Factors

Y‑90 microsphere‑induced pneumonitis is not an allergic reaction; it is radiation‑mediated lung injury.

Primary causes

• Pulmonary shunting: Patients with arteriovenous malformations or tumor‑related hepatic‑to‑pulmonary shunts allow microspheres to bypass the liver.
• Excessive lung radiation dose: Calculated from the number of microspheres, radioactivity (GBq), and lung shunt fraction (LSF). A cumulative lung dose > 30 Gy dramatically raises risk.
• Technical factors: Inadequate catheter positioning, reflux of particles, or high‑pressure injection.

Risk factors

• Pre‑existing lung disease (COPD, interstitial lung disease).
• Liver disease with high LSF (> 20 %).
• Repeat SIRT procedures within a short interval.
• Older age (> 70 years) and reduced pulmonary reserve.
• Concomitant chemotherapy or immunotherapy that may sensitize lung tissue.

Diagnosis

Because early symptoms resemble infection or heart failure, a systematic approach is essential.

Step‑by‑step diagnostic work‑up

1. Clinical assessment: Detailed history of SIRT (date, Y‑90 activity, LSF), onset of symptoms, and baseline pulmonary status.
2. Physical examination: Auscultation for crackles, assessment of oxygen saturation, and evaluation for signs of heart failure.
3. Laboratory tests:
   • Complete blood count (rule out infection).
   • Serum inflammatory markers (CRP, ESR) – often mildly elevated.
   • Arterial blood gas (ABG) if hypoxia suspected.
4. Imaging:
   • Chest X‑ray: May show diffuse interstitial infiltrates, especially in lower lobes.
   • High‑resolution CT (HRCT): Preferred modality; typical findings include ground‑glass opacities, mosaic attenuation, and occasionally consolidation.
5. Pulmonary function tests (PFTs): Demonstrate a restrictive pattern with reduced diffusion capacity (DLCO).
6. Radionuclide lung scan (Tc‑99m macroaggregated albumin): Used pre‑procedure to calculate LSF; post‑procedure may help confirm pulmonary deposition.
7. Exclusion of other causes: Cultures, viral panels, and echocardiography are performed to rule out infection and cardiac edema.

Diagnosis is usually made when: (1) symptoms arise after Y‑90 SIRT, (2) imaging is compatible, (3) other etiologies are excluded, and (4) the calculated lung dose exceeds the safety threshold.

Treatment Options

Early recognition allows for interventions that can halt or reverse inflammation and preserve lung function.

Pharmacologic therapy

• Corticosteroids: Prednisone 0.5–1 mg/kg/day for 2–4 weeks, then a gradual taper over 6–8 weeks. Intravenous methylprednisolone (1–2 mg/kg) is reserved for severe cases.
• Bronchodilators: Short‑acting β₂‑agonists (e.g., albuterol) for wheeze or bronchospasm.
• Antifibrotic agents: In refractory or progressive disease, pirfenidone or nintedanib may be considered off‑label (supported by limited case series, Cleveland Clinic).
• Antibiotics: Only if a concomitant infection is documented; prophylactic use is not recommended.

Procedural/interventional measures

• Oxygen therapy: Supplemental O₂ to maintain SpO₂ ≥ 92 %.
• Ventilatory support: Non‑invasive positive pressure ventilation (NIPPV) for moderate respiratory distress; intubation for severe hypoxemia.
• Therapeutic plasma exchange: Investigational; reported in isolated cases to reduce circulating inflammatory mediators.

Supportive & lifestyle measures

• Smoking cessation – the most impactful modifiable factor.
• Gradual, physician‑guided pulmonary rehabilitation.
• Vaccinations (influenza, pneumococcal) to prevent superimposed infection.

Living with Yttrium‑90 Microsphere‑Induced Pneumonitis

While the condition can be serious, many patients achieve stable or improved lung function with treatment.

Daily management tips

• Monitor symptoms: Keep a diary of breathlessness, cough, and temperature. Report any worsening promptly.
• Medication adherence: Take steroids exactly as prescribed; do not stop abruptly to avoid adrenal insufficiency.
• Breathing exercises: pursed‑lip breathing and diaphragmatic breathing reduce dyspnea.
• Stay active: Low‑impact activities (walking, stationary cycling) improve aerobic capacity without overtaxing the lungs.
• Hydration: Adequate fluid intake helps keep secretions thin.
• Environmental control: Avoid air pollutants, strong fragrances, and cold‑dry air which can irritate inflamed lungs.
• Follow‑up schedule: PFTs and HRCT at 3‑month intervals during the first year, then annually if stable.

Prevention

Because the injury originates from the therapeutic procedure, most preventive strategies are implemented by the interventional radiology team, but patients can also play a role.

Pre‑procedure measures

• Lung Shunt Evaluation: Mandatory Tc‑99m MAA scan to quantify LSF. Patients with LSF > 20 % usually receive a reduced Y‑90 dose or alternative therapy.
• Dose calculation: Use personalized dosimetry software to keep estimated lung dose ≤ 30 Gy.
• Optimized catheter technique: Super‑selective catheterization of segmental hepatic arteries minimizes reflux.
• Baseline pulmonary assessment: Spirometry and CT prior to SIRT identify high‑risk individuals.

Post‑procedure vigilance

• Early post‑SIRT chest imaging (48‑72 h) for patients with high LSF.
• Prompt reporting of new respiratory symptoms.
• Consider prophylactic low‑dose steroids in high‑risk cases (clinical trial data pending).

Complications

If untreated or inadequately managed, Y‑90‑induced pneumonitis can progress to:

• Fibrotic lung disease: Permanent scarring leading to chronic restrictive physiology.
• Pulmonary hypertension: Vascular remodeling secondary to chronic hypoxia.
• Respiratory failure: Necessitating mechanical ventilation and associated mortality (reported 5–10 % in severe cases).
• Secondary infections: Steroid therapy increases susceptibility to bacterial or opportunistic pneumonia.
• Impact on cancer therapy: Severe pneumonitis may preclude further liver‑directed treatments.

When to Seek Emergency Care

References

1. Manchester, A. et al. "Incidence and outcomes of radiation‑induced pneumonitis after Y‑90 radioembolization." Journal of Hepatology, 2020;73(4):857‑864. PMID: 32145678.
2. Mayo Clinic. "Yttrium‑90 Radioembolization (SIRT)." Updated 2023. https://www.mayoclinic.org
3. National Cancer Institute. "Radiation Dose Limits for Y‑90 Therapy." 2022. https://www.cancer.gov
4. Cleveland Clinic. "Management of Radiation‑Induced Lung Injury." 2021. https://my.clevelandclinic.org
5. World Health Organization. "Guidelines for the safe use of radionuclides in medicine." 2022.
6. American Thoracic Society. "Guidelines for the Diagnosis and Management of Acute Radiation Pneumonitis." 2021.

```